Stockscreener 앱 받기
1.66%
시장 영업 전:
Amgen Inc 주식(AMGN)의 최신 뉴스
OFI Invest Asset Management Increases Stock Position in Amgen Inc. $AMGN - MarketBeat
Prime Capital Investment Advisors LLC Has $6.32 Million Stake in Amgen Inc. $AMGN - MarketBeat
Encompass Wealth Advisors Trims Amgen Stake by Over 50% - National Today
Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033 - GlobeNewswire Inc.
Amgen's lung cancer drug tarlatamab wins China approval - Reuters
Is Amgen (AMGN) One of the Most Profitable Value Stocks to Buy Right Now? - Yahoo Finance
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
What Amgen (AMGN)'s TEPEZZA On‑Body Injector Phase 3 Results Mean For Shareholders - simplywall.st
Lobbying Update: $50,000 of TIBER CREEK HEALTH STRATEGIES INC. ON BEHALF OF AMGEN INC. lobbying was just disclosed - Quiver Quantitative
Guggenheim Adjusts Amgen (AMGN) Price Target to $351, Maintains - GuruFocus
Investors heavily search Amgen Inc. (AMGN): Here is what you need to know - MSN
Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs (NASDAQ:AMGN) - Seeking Alpha
Guggenheim Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $351 - Moomoo
Guggenheim raises Amgen stock price target to $351 on product mix - Investing.com Canada
Amgen (AMGN) Stock: GLP-1 Drug MariTide Drives Analyst Optimism - CoinCentral
We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play. - Barron's
Cantor Fitzgerald Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $350 - Moomoo
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Amgen (AMGN) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen (NASDAQ:VRDN) - Seeking Alpha
Truist raises Amgen stock price target to $325 on revenue outlook - Investing.com
Amgen’s Tepezza On Body Injector Data Tests Thyroid Eye Disease Moat - simplywall.st
Is Amgen Stock Poised For A Rally? - Trefis
Cantor Fitzgerald maintains Amgen stock rating ahead of earnings - Investing.com
Amgen releases positive topline results from phase 3 trial of teprotumumab-trbw (TEPEZZA) - Ophthalmology Times
BIP Wealth LLC Boosts Amgen Stake by Over 800% - National Today
BIP Wealth LLC Acquires 8,785 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition - Yahoo Finance
Amgen Inc CEO Robert A. Bradway 2025 total compensation $24.7 million - marketscreener.com
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN) - Seeking Alpha
Amgen Stock Price Expected to Rise, Analyst Says - National Today
Stifel sees path towards differentiation for Viridian after Amgen data - Yahoo Finance
Amgen Shares Sold by KFG Wealth Management - National Today
Investors Are Actively Looking Into Amgen Inc. (AMGN): Key Information You Should Be Aware Of - Bitget
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance Singapore
AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease - Yahoo Finance Singapore
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
ONTARIO AND QUEBEC EXPAND PUBLIC COVERAGE OF REPATHA® FOR ELIGIBLE RECENT ACUTE CORONARY SYNDROME PATIENTS - Newswire Canada
Oncolytic Virus Therapies Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | CG Oncology, Imugene, Amgen, Daiichi Sankyo, Genelux, Replimune, Binhui Biopharma - Barchart
Robinhood Asset Management LLC Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by KFG Wealth Management LLC - MarketBeat
Amgen reports positive Phase III findings for subcutaneous Tepezza trial - Yahoo
Citi Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $345 - Moomoo
Amgen's new subcutaneous Tepezza scores Phase III boost - The Pharma Letter
Aaron Wealth Advisors LLC Sells 15,498 Shares of Amgen Inc. $AMGN - MarketBeat
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. - Barron's
Viridian Therapeutics stock tumbles after Amgen Tepezza data - Investing.com
Under-the-skin Tepezza comparable to infused version in key study, Amgen says - BioPharma Dive
Amgen’s Subcutaneous Tepezza Scores In TED As More Convenient Version - Citeline News & Insights
William Blair Maintains Amgen(AMGN.US) With Buy Rating - Moomoo
Amgen (AMGN) Reports Positive Phase 3 Results for Tepezza in Thy - GuruFocus
Analysts’ Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS) - The Globe and Mail
Why Is Viridian Therapeutics Stock Sinking Monday?Amgen (NASDAQ:AMGN), Viridian Therapeutics (NASDAQ:V - Benzinga
William Blair reiterates Amgen stock rating on positive Tepezza data - Investing.com
Viridian Shares Fall After Competing Amgen Eye Drug Performs Well - Moomoo
Amgen (AMGN) Achieves Impressive Phase 3 Results with Tepezza - GuruFocus
Amgen Posts 77% Response In Thyroid Eye Disease Study - Benzinga
Systemic Sclerosis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Boehringer Ingelheim, Roche, Zenyaku Kogyo, Chugai Pharma, Kyowa Kirin, GSK, AstraZeneca, Amgen - barchart.com
Amgen (AMGN) Reveals Positive Phase 3 Results for Subcutaneous T - GuruFocus
Amgen scores with trial of on-body injected version of Tepezza in thyroid eye disease - Fierce Pharma
Amgen Inc. stock: Pipeline pivot eyes $37-38B sales amid biosimilar risks - AD HOC NEWS
Buffalo Business & Estate Services Ltd. Takes Position in Amgen Inc. $AMGN - MarketBeat
BXM Wealth LLC Increases Stock Position in Amgen Inc. $AMGN - marketbeat.com
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh Trade Ideas — BMFBOVESPA:AMGN34 - TradingView
0.39%
0.45%
자본화:
|
볼륨(24시간):